Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Hallucinogen
gptkb:amphetamine |
| gptkbp:CASNumber |
69587-11-7
|
| gptkbp:category |
gptkb:recreational_drug
gptkb:Hallucinogen |
| gptkbp:chemicalFormula |
C10H14INO2
|
| gptkbp:developedBy |
gptkb:Alexander_Shulgin
|
| gptkbp:effect |
euphoria
hallucinations stimulation visual enhancement |
| gptkbp:firstSynthesized |
1970s
|
| gptkbp:IUPACName |
2-(4-iodo-2,5-dimethoxyphenyl)ethanamine
|
| gptkbp:legalStatus |
gptkb:Schedule_III_(Canada)
gptkb:Schedule_I_(United_States) gptkb:Class_A_(United_Kingdom) |
| gptkbp:meltingPoint |
205–207 °C
|
| gptkbp:molecularWeight |
307.13 g/mol
|
| gptkbp:publishedIn |
gptkb:PiHKAL
|
| gptkbp:relatedTo |
gptkb:2C-E
gptkb:2C-B |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:bfsParent |
gptkb:NBOMe_series
gptkb:2C_family |
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
2C-I
|